• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Tempest Therapeutics Inc.

    5/9/22 5:26:59 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPST alert in real time by email
    SC 13D 1 d357158dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2(a)

    (Amendment No. )*

     

     

    Tempest Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    87978U108

    (CUSIP Number)

    Versant Venture Capital VI, L.P.

    Robin L. Praeger

    One Sansome Street, Suite 3630

    San Francisco, CA 94104

    415-801-8100

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 29, 2022

     

     

    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Venture Capital VI, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      997,940 shares of Common Stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      997,940 shares of Common Stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      997,940 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      9.7% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by Versant Venture Capital IV, L.P. (“Versant IV”), Versant Side Fund IV, L.P. (“Side Fund IV”), Versant Ventures IV, LLC (“LLC IV”), Versant Venture Capital VI, L.P. (“Versant VI”), Versant Ventures VI GP, L.P. (“GP VI”), Versant Ventures VI GP-GP, LLC (“LLC VI”), Versant Vantage II, L.P. (“Vantage II LP”), Versant Vantage II GP, L.P. (“Vantage II GP”), Versant Vantage II GP-GP, LLC (“Vantage II LLC” and, with Versant IV, Side Fund IV, LLC IV, Versant VI, GP VI, LLC VI, Vantage II LP and Vantage II GP, collectively, the “Reporting Persons”). LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting and dispositive power over the shares held by Versant IV and Side Fund IV. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting and dispositive power over the shares held by Versant VI. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting and dispositive power over the shares held by Vantage II LP. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures VI GP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      997,940 shares of Common Stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      997,940 shares of Common Stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      997,940 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      9.7% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures VI GP-GP, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      997,940 shares of Common Stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      997,940 shares of Common Stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      997,940 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      9.7% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage II, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      2,118,644 shares of Common Stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      2,118,644 shares of Common Stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,118,644 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      20.5% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Vantage II LLC and Vantage II GP share voting and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage II GP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      2,118,644 shares of Common Stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      2,118,644 shares of Common Stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,118,644 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      20.5% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Vantage II LLC and Vantage II GP share voting and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage II GP-GP, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      2,118,644 shares of Common Stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      2,118,644 shares of Common Stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,118,644 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      20.5% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Vantage II LLC and Vantage II GP share voting and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Venture Capital IV, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         7.     

      Sole Voting Power

     

      1,171,094 shares of Common Stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      1,171,094 shares of Common Stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,171,094 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      11.3% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant IV. LLC IV is the general partner of Versant IV and has voting and dispositive power over the shares held by Versant IV and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Side Fund IV, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      7,377 shares of Common Stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      7,377 shares of Common Stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      7,377 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      0.1% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Side Fund IV. LLC IV is the general partner of Side Fund IV and has voting and dispositive power over the shares held by Side Fund IV and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures IV, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      1,178,471 shares of Common Stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      1,178,471 shares of Common Stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,178,471 shares of Common Stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      11.4% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    Includes (i) 1,171,094 shares held by Versant IV; and (ii) 7,377 shares held by Side Fund IV. LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting and dispositive power over the shares held by each of Versant IV and Side Fund IV and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 10,323,006 shares of the Issuer’s Common Stock outstanding as reported by the Issuer to the Reporting Persons on May 2, 2022.


    CUSIP No. 87978U108                                                                                          13D

     

     

    Explanatory Note:

    Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. The Reporting Persons previously filed a statement on Schedule 13G with respect to the Issuer on February 11, 2022 and are filing this statement to report an acquisition that is subject to Schedule 13D pursuant to Rule 13d-1(f) under the Securities Exchange Act of 1934.

    Item 1. Security and Issuer

    This joint statement on Schedule 13D (this “Statement”) is filed with respect to the common stock (the “Common Stock”) of Tempest Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (the “Issuer”). The address of the principal executive offices of the Issuer is 7000 Shoreline Court, Suite 275, South San Francisco, CA 94080.

    Item 2. Identity and Background

    (a) This Statement is filed by Versant Venture Capital IV, L.P. (“Versant IV”), Versant Side Fund IV, L.P. (“Side Fund IV”), Versant Ventures IV, LLC (“LLC IV”), Versant Venture Capital VI, L.P. (“Versant VI”), Versant Ventures VI GP, L.P. (“GP VI”), Versant Ventures VI GP-GP, LLC (“LLC VI”), Versant Vantage II, L.P. (“Vantage II LP”), Versant Vantage II GP, L.P. (“Vantage II GP”), Versant Vantage II GP-GP, LLC (“Vantage II LLC” and, with Versant IV, Side Fund IV, LLC IV, Versant VI, GP VI, LLC VI, Vantage II LP and Vantage II GP, collectively, the “Reporting Persons”). The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached hereto as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.

    (b) The address of the principal offices of each Reporting Person is One Sansome Street, Suite 3630, San Francisco, CA 94104.

    (c) Each of Versant IV, Side Fund IV, Versant VI and Vantage II LP are venture capital investment entities and each of LLC IV, GP VI, LLC VI, Vantage II GP and Vantage II LLC are the respective general partners of the venture capital investment entities.

    (d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Each of the Reporting Persons is organized in the state of Delaware.

    Item 3. Source and Amount of Funds or Other Considerations

    In connection with the merger of Millendo Therapeutics, Inc. (“Millendo”) and private company Tempest Therapeutics, Inc. (“Tempest”), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the “Merger Agreement”), which closed on June 25, 2021 (the “Closing”), each share of Tempest’s common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The exchange ratio gives effect to the 15-to-1 reverse stock split of Millendo’s common stock that occurred in connection with the Merger Agreement. Upon the closing, Millendo was renamed as the Issuer. After the Closing, Versant IV held 1,171,094 shares of the Issuer’s Common Stock, Side Fund IV held 7,377 shares of the Issuer’s Common Stock and Versant VI held 997,940 shares of the Issuer’s Common Stock.


    On April 26, 2022, the Issuer, Vantage II LP and certain other investors entered into a Securities Purchase Agreement (the “PIPE Agreement”), which closed on April 29, 2022 (the “PIPE Financing”). Vantage II LP purchased 2,118,644 shares of the Issuer’s Common Stock in the PIPE Financing for a purchase price of $2.36 per share and an aggregate purchase price of $4,999,999.84.

    Item 4. Purpose of Transaction

    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional Ordinary Shares or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of the Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer’s business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise.

    Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

    Item 5. Interest in Securities of the Issuer

    (a) and (b) See Items 7-11 of the cover pages of this Statement and Item 2 above.

    (c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer’s securities within the past 60 days.

    (d) Under certain circumstances set forth in the respective limited partnership agreements of each of Versant IV, Versant VI and Vantage II LP (the “Funds”), the respective general partners and limited partners of the Funds may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    In connection with the PIPE Financing, Vantage II LP entered into the PIPE Agreement with the Issuer for the purchase of 2,118,644 shares of the Issuer’s Common Stock at $2.36 per share. The terms and provisions of the PIPE Agreement are described more fully in the Issuer’s Current Report on Form 8-K (File No. 001-35890) filed with the U.S. Securities and Exchange Commission (the “Commission”) on May 2, 2022 (the “Form 8-K”), and the above summary is qualified by reference to such description and the full text of the PIPE Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.

    In connection with its purchase of shares of the Issuer’s Common Stock pursuant to the PIPE Agreement, Vantage II LP and certain of the Issuer’s other investors entered into a Registration Rights Agreement, dated April 26, 2022, with the Issuer (the “Rights Agreement”). After the closing of the PIPE Financing, the stockholders party thereto are entitled to certain registration rights, including the right to demand that that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The terms and provisions of the Rights Agreement are described more fully in the Form 8-K, and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 3 to this Statement and is incorporated herein by reference.


    Item 7. Materials to be Filed as Exhibits

     

    Exhibit 1:    Joint Filing Agreement, dated May 9, 2022, by and among the Reporting Persons (filed herewith).
    Exhibit 2:    Securities Purchase Agreement, dated as of April 26, 2022, by and among the Issuer, Vantage II LP and certain other investors (filed as Exhibit 10.1 to the Issuer’s Current Report on Form 8-K as filed with the Commission on May 2, 2022 (File No. 001-35890) and incorporated herein by reference).
    Exhibit 3:    Registration Rights Agreement, by and among the Issuer and certain of its stockholders (filed as Exhibit 10.2 to the Issuer’s Current Report on Form 8-K as filed with the Commission on May 2, 2022 (File No. 001-35890) and incorporated herein by reference).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    May 9, 2022

     

    Versant Venture Capital VI, L.P.
    By:   Versant Ventures VI GP, L.P.
    Its:   General Partner
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:  

    /s/ Robin L. Praeger

    Versant Ventures VI GP, L.P.
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:  

    /s/ Robin L. Praeger

    Versant Ventures VI GP-GP, LLC
    By:  

    /s/ Robin L. Praeger

    Versant Vantage II, L.P.
    By:   Versant Vantage II GP, L.P.
    Its:   General Partner
    By:   Versant Vantage II GP-GP, LLC
    Its:   General Partner
    By:  

    /s/ Robin L. Praeger

    Versant Vantage II GP, L.P.
    By:   Versant Vantage II GP-GP, LLC
    Its:   General Partner
    By:  

    /s/ Robin L. Praeger

    Versant Vantage II GP-GP, LLC
    By:  

    /s/ Robin L. Praeger

    Versant Venture Capital IV, L.P.
    By:   Versant Ventures IV, LLC
    Its:   General Partner
    By:  

    /s/ Robin L. Praeger

    Versant Venture Capital IV, L.P.
    By:   Versant Vantage IV, LLC
    Its:   General Partner
    By:  

    /s/ Robin L. Praeger

    Versant Side Fund IV, L.P.
    By:   Versant Ventures IV, LLC
    Its:   General Partner
    By:  

    /s/ Robin L. Praeger

    Versant Ventures IV, LLC
    By:  

    /s/ Robin L. Praeger

     

    Get the next $TPST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TPST

    DatePrice TargetRatingAnalyst
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    4/10/2025Buy → Neutral
    H.C. Wainwright
    3/14/2024$13.00Sector Outperform
    Scotiabank
    2/8/2024$15.00Buy
    Jefferies
    10/21/2021Outperform
    William Blair
    7/13/2021$51.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Brady Stephen R

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:25 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Maestas Nicholas

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:20 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Corporate Controller Trojanowski Justin

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:22 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Tempest Therapeutics downgraded by Scotiabank

      Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

      4/10/25 8:50:49 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

      4/10/25 8:03:29 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Tempest Therapeutics with a new price target

      Scotiabank initiated coverage of Tempest Therapeutics with a rating of Sector Outperform and set a new price target of $13.00

      3/14/24 8:21:09 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TPST
    Leadership Updates

    Live Leadership Updates

    See more

    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

      SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      8/12/24 8:59:00 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Tempest Therapeutics Inc. (Amendment)

      SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      5/13/24 4:54:01 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tempest Therapeutics Inc. (Amendment)

      SC 13G/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      2/14/24 6:49:42 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

      BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John

      9/18/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

      BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Troy M. Wagner as Vice President of Quality Assurance. "Troy brings a wealth of experience in late-stage product development, including managing quality systems across a range of global clinical studies and assisting with global regulatory filings. We look forward to her contributions as we move towards Phase 3 development of amezalpat to treat hepatocellular carcinoma and are thrilled to have her join the Tempest leadership team,"

      8/21/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

      BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors.   Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer

      11/11/21 9:00:00 AM ET
      $QGEN
      $TPST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

      BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation of new data supporting the immune component of amezalpat's purported dual mechanism of action that reinforces its potential as a novel cancer treatment at the 2025 American Association for Cancer Research (AACR) Annual Meeting. "The data presented at the AACR Annual Meeting show that amezalpat reduced tumor promoting immunosuppression by M2 macrophages and T regulatory cells resulting in immune activation. These data support the immune

      4/28/25 4:05:00 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

      BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company's novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP). "Receiving orphan drug designation for TPST-1495, our second clinical program, is a significant milestone in our mission to bring innovative therapies to patients with unmet medical need," said Stephen Br

      4/21/25 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

      Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC Received FDA "Study May Proceed" letter for TPST-1495 in a Phase 2 trial for the treatment of familial adenomatous polyposis (FAP); data expected 2026 BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the c

      4/9/25 4:30:00 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Financials

    Live finance-specific insights

    See more
    • Tempest Extends Limited Duration Stockholder Rights Plan

      BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or the "Company"), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the "Board") has adopted an amendment to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan until the Annual Meeting of Stockholders. "Given the significant milestones reached this year in the amezalpat program – the positive survival data compared to standard of care and broad agreement with FDA on the Phase 3 path – coupled

      10/10/24 7:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

      21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves OS is the primary regulatory endpoint for first-line HCCCompany to host webcast conference call today at 8:30am ET BRISBANE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new positive data from the ongoing global randomized Phase 1b/2 clinica

      6/20/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

      BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global randomized Phase 1b/2 combination study of amezalpat (TPST-1120) with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register onlin

      6/18/24 6:22:51 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Tempest Therapeutics Inc.

      10-K/A - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/30/25 4:05:19 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Tempest Therapeutics Inc.

      8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/28/25 9:49:42 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Tempest Therapeutics Inc.

      8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/18/25 4:16:40 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/8/24 4:15:11 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/3/24 7:35:42 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/2/24 4:15:14 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care